Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
31
BCAX Quote, Financials, Valuation and Earnings
Last price:
$16.79
Seasonality move
:
-32.17%
Day range:
$16.71 - $17.30
52-week range:
$7.80 - $19.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.29x
Volume:
275.7K
Avg. volume:
688.9K
1-year change:
-12.13%
Market cap:
$920.3M
Revenue:
--
EPS (TTM):
-$2.23
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BCAX
Bicara Therapeutics, Inc.
|
-- | -$0.53 | -- | -74.03% | $30.75 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
DWTX
Dogwood Therapeutics, Inc.
|
-- | -- | -- | -- | $18.33 |
|
OTLC
Oncotelic Therapeutics, Inc.
|
-- | -- | -- | -- | -- |
|
PFE
Pfizer Inc.
|
$14B | $0.76 | -4.58% | 694.41% | $28.62 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BCAX
Bicara Therapeutics, Inc.
|
$16.80 | $30.75 | $920.3M | -- | $0.00 | 0% | -- |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$4.71 | $42.50 | $14.3M | -- | $0.00 | 0% | -- |
|
DWTX
Dogwood Therapeutics, Inc.
|
$4.07 | $18.33 | $9.3M | -- | $0.00 | 0% | -- |
|
OTLC
Oncotelic Therapeutics, Inc.
|
$0.08 | -- | $35.4M | -- | $0.00 | 0% | -- |
|
PFE
Pfizer Inc.
|
$25.09 | $28.62 | $142.7B | 14.62x | $0.43 | 6.86% | 2.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BCAX
Bicara Therapeutics, Inc.
|
0.49% | -0.726 | 0.23% | 13.80x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
DWTX
Dogwood Therapeutics, Inc.
|
0.23% | 6.290 | 0.14% | 3.90x |
|
OTLC
Oncotelic Therapeutics, Inc.
|
61.64% | -3.780 | 44.25% | 0.02x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BCAX
Bicara Therapeutics, Inc.
|
-$24K | -$40.7M | -26.37% | -26.44% | -- | -$29.3M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
DWTX
Dogwood Therapeutics, Inc.
|
-$17.3K | -$15.8M | -58.95% | -121.03% | -- | -$3.3M |
|
OTLC
Oncotelic Therapeutics, Inc.
|
-- | -$491K | -8.93% | -25.13% | -- | -$307K |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
Bicara Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns BCAX or AIM?
AIM ImmunoTech has a net margin of -- compared to Bicara Therapeutics, Inc.'s net margin of -10571.43%. Bicara Therapeutics, Inc.'s return on equity of -26.44% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital BCAXBicara Therapeutics, Inc.-- -$0.67 $404.8M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About BCAX or AIM?
Bicara Therapeutics, Inc. has a consensus price target of $30.75, signalling upside risk potential of 83.04%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Bicara Therapeutics, Inc., analysts believe AIM ImmunoTech is more attractive than Bicara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BCAXBicara Therapeutics, Inc.6 2 0 AIMAIM ImmunoTech1 0 0 -
Is BCAX or AIM More Risky?
Bicara Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock BCAX or AIM?
Bicara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicara Therapeutics, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCAX or AIM?
Bicara Therapeutics, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Bicara Therapeutics, Inc.'s net income of -$36.3M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Bicara Therapeutics, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicara Therapeutics, Inc. is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCAXBicara Therapeutics, Inc.-- -- -- -$36.3M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns BCAX or CVM?
CEL-SCI Corp. has a net margin of -- compared to Bicara Therapeutics, Inc.'s net margin of --. Bicara Therapeutics, Inc.'s return on equity of -26.44% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital BCAXBicara Therapeutics, Inc.-- -$0.67 $404.8M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About BCAX or CVM?
Bicara Therapeutics, Inc. has a consensus price target of $30.75, signalling upside risk potential of 83.04%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 802.34%. Given that CEL-SCI Corp. has higher upside potential than Bicara Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Bicara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BCAXBicara Therapeutics, Inc.6 2 0 CVMCEL-SCI Corp.1 0 0 -
Is BCAX or CVM More Risky?
Bicara Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock BCAX or CVM?
Bicara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicara Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCAX or CVM?
Bicara Therapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Bicara Therapeutics, Inc.'s net income of -$36.3M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Bicara Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicara Therapeutics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCAXBicara Therapeutics, Inc.-- -- -- -$36.3M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns BCAX or DWTX?
Dogwood Therapeutics, Inc. has a net margin of -- compared to Bicara Therapeutics, Inc.'s net margin of --. Bicara Therapeutics, Inc.'s return on equity of -26.44% beat Dogwood Therapeutics, Inc.'s return on equity of -121.03%.
Company Gross Margin Earnings Per Share Invested Capital BCAXBicara Therapeutics, Inc.-- -$0.67 $404.8M DWTXDogwood Therapeutics, Inc.-- -$8.20 $77.6M -
What do Analysts Say About BCAX or DWTX?
Bicara Therapeutics, Inc. has a consensus price target of $30.75, signalling upside risk potential of 83.04%. On the other hand Dogwood Therapeutics, Inc. has an analysts' consensus of $18.33 which suggests that it could grow by 350.45%. Given that Dogwood Therapeutics, Inc. has higher upside potential than Bicara Therapeutics, Inc., analysts believe Dogwood Therapeutics, Inc. is more attractive than Bicara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BCAXBicara Therapeutics, Inc.6 2 0 DWTXDogwood Therapeutics, Inc.0 0 0 -
Is BCAX or DWTX More Risky?
Bicara Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dogwood Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BCAX or DWTX?
Bicara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dogwood Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicara Therapeutics, Inc. pays -- of its earnings as a dividend. Dogwood Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCAX or DWTX?
Bicara Therapeutics, Inc. quarterly revenues are --, which are smaller than Dogwood Therapeutics, Inc. quarterly revenues of --. Bicara Therapeutics, Inc.'s net income of -$36.3M is lower than Dogwood Therapeutics, Inc.'s net income of -$15.7M. Notably, Bicara Therapeutics, Inc.'s price-to-earnings ratio is -- while Dogwood Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicara Therapeutics, Inc. is -- versus -- for Dogwood Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCAXBicara Therapeutics, Inc.-- -- -- -$36.3M DWTXDogwood Therapeutics, Inc.-- -- -- -$15.7M
-
Which has Higher Returns BCAX or OTLC?
Oncotelic Therapeutics, Inc. has a net margin of -- compared to Bicara Therapeutics, Inc.'s net margin of --. Bicara Therapeutics, Inc.'s return on equity of -26.44% beat Oncotelic Therapeutics, Inc.'s return on equity of -25.13%.
Company Gross Margin Earnings Per Share Invested Capital BCAXBicara Therapeutics, Inc.-- -$0.67 $404.8M OTLCOncotelic Therapeutics, Inc.-- -$0.00 $22.6M -
What do Analysts Say About BCAX or OTLC?
Bicara Therapeutics, Inc. has a consensus price target of $30.75, signalling upside risk potential of 83.04%. On the other hand Oncotelic Therapeutics, Inc. has an analysts' consensus of -- which suggests that it could grow by 4902.5%. Given that Oncotelic Therapeutics, Inc. has higher upside potential than Bicara Therapeutics, Inc., analysts believe Oncotelic Therapeutics, Inc. is more attractive than Bicara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BCAXBicara Therapeutics, Inc.6 2 0 OTLCOncotelic Therapeutics, Inc.0 0 0 -
Is BCAX or OTLC More Risky?
Bicara Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oncotelic Therapeutics, Inc. has a beta of -0.758, suggesting its less volatile than the S&P 500 by 175.831%.
-
Which is a Better Dividend Stock BCAX or OTLC?
Bicara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncotelic Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicara Therapeutics, Inc. pays -- of its earnings as a dividend. Oncotelic Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCAX or OTLC?
Bicara Therapeutics, Inc. quarterly revenues are --, which are smaller than Oncotelic Therapeutics, Inc. quarterly revenues of --. Bicara Therapeutics, Inc.'s net income of -$36.3M is lower than Oncotelic Therapeutics, Inc.'s net income of -$1.1M. Notably, Bicara Therapeutics, Inc.'s price-to-earnings ratio is -- while Oncotelic Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicara Therapeutics, Inc. is -- versus -- for Oncotelic Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCAXBicara Therapeutics, Inc.-- -- -- -$36.3M OTLCOncotelic Therapeutics, Inc.-- -- -- -$1.1M
-
Which has Higher Returns BCAX or PFE?
Pfizer Inc. has a net margin of -- compared to Bicara Therapeutics, Inc.'s net margin of 21.32%. Bicara Therapeutics, Inc.'s return on equity of -26.44% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital BCAXBicara Therapeutics, Inc.-- -$0.67 $404.8M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About BCAX or PFE?
Bicara Therapeutics, Inc. has a consensus price target of $30.75, signalling upside risk potential of 83.04%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.08%. Given that Bicara Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Bicara Therapeutics, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings BCAXBicara Therapeutics, Inc.6 2 0 PFEPfizer Inc.7 15 1 -
Is BCAX or PFE More Risky?
Bicara Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock BCAX or PFE?
Bicara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.86% to investors and pays a quarterly dividend of $0.43 per share. Bicara Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios BCAX or PFE?
Bicara Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Bicara Therapeutics, Inc.'s net income of -$36.3M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Bicara Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicara Therapeutics, Inc. is -- versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCAXBicara Therapeutics, Inc.-- -- -- -$36.3M PFEPfizer Inc.2.28x 14.62x $16.7B $3.6B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
